Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

CEConversations

CEConversations artwork

Optimizing Early Breast Cancer Outcomes in the Community Setting: An Expert Review of Emerging Therapies and Evolving Standards of Care in HR+/HER2- Disease

Nov 15, 20221 hr 2 minAudio
ShareXLinkedInFacebookWhatsAppEmail

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/ebc-gr-podcast Learning Objectives Review the epidemiology and clinical characteristics of HR+, HER2- early-breast cancer (EBC), and identify patients at an elevated risk of disease recurrence as a means of guiding treatment. Appraise the current treatment landscape in HR+, HER2- EBC, including the established and emerging evidentiary base for novel therapies in the adjuvant setting, expert consensus guidelines, and FDA-approved indications. Recognize treatment-related adverse events associated with oral therapies used in HR+, HER2- EBC and implement evidence-supported mitigation and management protocols. Using real-world patient case examples, design on-label treatment plans for HR+, HER2- EBC at high risk for recurrence, emphasizing the critical need for effective communication and coordination strategies among the multidisciplinary community-based breast cancer care team. Evaluate adaptive approaches for promoting adherence and persistence to oral anticancer therapies, highlighting common reasons for noncompliance and the impact of patient counseling and shared decision-making (SDM). Presented by: Hope S. Rugo, MD Professor, Division of Hematology/Oncology Director, Breast Oncology Clinical Trials Education UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, CA Presented by Creative Educational Concepts, LLC. Supported through an independent educational grant from Lilly.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Webcast Finding the Right Rhythm: Supporting Pediatric Oncology Nurses in Longitudinal NF1 Management

    Oct 28, 202656 minAudio

    In this CE Concepts recorded symposium, faculty will apply NF1 diagnostic and oncologic monitoring guidelines to support early recognition of NF1-PNs in pediatric patients. Learners will be shown how to incorporate MEK...

    Credit the people on this episode

  2. Webcast: Rare, Complex, and Under-Recognized: Supporting Oncology Nurses in the Care of Patients with NF1

    Aug 6, 202652 minAudio

    Neurofibromatosis type 1 (NF1) is a rare, complex, and often under-recognized condition that presents significant diagnostic and management challenges, particularly for oncology nurses who play a central role in...

    Credit the people on this episode

  3. Evolving Paradigms in Immuno-Oncology: Optimizing Patient Care Through Innovative Delivery Approaches of Immune Checkpoint Inhibitors

    Jul 1, 202632 minAudio

    Immune checkpoint inhibitors (ICIs) have transformed the landscape of oncology, achieving remarkable outcomes across tumor types. As outcomes improve and focus shifts to patient-centered care, however, the burden of...

    Credit the people on this episode

  4. Targeting the Pathway: Evolving Roles of MEK Inhibitors in NF1-Associated PN

    Jul 1, 20261 hr 4 minAudio

    Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder characterized by tumor predisposition and a wide spectrum of neurologic manifestations. Among its most serious complications are plexiform...

    Credit the people on this episode

  5. Exploring the Horizons in Advanced or Recurrent Endometrial Cancer: Practical Considerations and Future Directions for New Treatment Strategies

    Jul 1, 20261 hr 5 minAudio

    Despite significant advances in the management of advanced or recurrent endometrial cancer (EC) - including the use of molecular classification, immune checkpoint inhibitors, and targeted therapies - delivering timely,...

    Credit the people on this episode